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Abstract
Objective. To develop and validate a model of a clinical trial that evaluates the changes in cholesterol level as a surrogate marker for
lipodystrophy in HIV subjects under alternative antiretroviral regimes, i.e., treatment with Protease Inhibitors vs. a combination of nevi-
rapine and other antiretroviral drugs.
Methods. Five simulation models were developed based on diﬀerent assumptions, on treatment variability and pattern of cholesterol
reduction over time. The last recorded cholesterol level, the diﬀerence from the baseline, the average diﬀerence from the baseline and level
evolution, are the considered endpoints. Speciﬁc validation criteria based on a 10% minus or plus standardized distance in means and
variances were used to compare the real and the simulated data.
Results. The validity criterion was met by all models for considered endpoints. However, only two models met the validity criterion
when all endpoints were considered. The model based on the assumption that within-subjects variability of cholesterol levels changes
over time is the one that minimizes the validity criterion, standardized distance equal to or less than 1% minus or plus.
Conclusion. Simulation is a useful technique for calibration, estimation, and evaluation of models, which allows us to relax the often
overly restrictive assumptions regarding parameters required by analytical approaches. The validity criterion can also be used to select
the preferred model for design optimization, until additional data are obtained allowing an external validation of the model.
 2006 Elsevier Inc. All rights reserved.
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1. Introduction
Randomized clinical trials are performed to compare
the eﬀect of a new treatment with a control treatment
(existing treatment or placebo). The overall objective of
the clinical trial is to predict the eﬀect of treatment on
the whole population. These trials can be viewed as a
physical (real) model aiming to assess the valid result of
an experiment [1,2], on subjects with very restrictive selec-
tion criteria and treated in experimental conditions [3].
However, in many cases, the true eﬀect of treatment is
not assessed in practice due to low external validity of
the experiment results [4]. Similarly, simulation models
of clinical trials are mathematical models viewed as a vir-
tual representation of a clinical trial aiming to describe
the evolution or changes of all or some of the variables
of interest at particular points in time. In addition to esti-
mating the results, these models are used for analysis,
hypothesis testing, research planning and prediction of
the evolution and results of treated disease. Constructing
these models involves the selection of relevant aspects of
the indented objectives, and leaving aside aspects which
are considered irrelevant.
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These simulation models can be used to retrospectively
assess the appropriateness of clinical trial design and to
prospectively optimize the design of future trials. They
might also help decision-makers to decide whether to con-
tinue or discontinue a clinical trial. Models should be val-
idated as part of their development process. Computer
simulation has proven a useful tool for model validation
and, consequently, for guaranteeing the intended results
[5]. From another perspective, simulation models are
accepted across disciplines as providing relevant informa-
tion on the real system. This information can be deﬁned
as the adjustment between satisfaction and truth on how
the system works [6]. Therefore, when the distance between
the simulation model and the truth decreases, satisfaction
with the results increases and vice versa.
Two diﬀerent approaches to validating a model are pro-
posed in the literature: (1) a conceptual validation ensuring
that model objectives, structures, and hypotheses are
appropriately implemented and make sense to people
who have good knowledge of the problem [7] and, (2) a
computer model validation that includes model veriﬁca-
tion, retrospective validation in which model parameters
are adjusted to the observed data [7,8], and prospective val-
idations that are performed either with concurrent data
from simultaneous clinical trials or with future clinical data
to predict parameters that model upcoming clinical trials
[7]. Retrospective validation, also known as operational
validation or results validation [9–11], can be subdivided
into internal validation and external validation [12]. Inter-
nal validation is usually performed when data used to build
the model are compared with data generated by the model;
while external validation is assessed when the data from
other clinical trials are compared to data given by the mod-
el [13–15]. Quantitative comparisons based on hypothesis
testing (taking in Conﬁdence Intervals) are commonly used
to assess operational validation since they allow an objec-
tive decision [10].
Patten [16] developed Markov models with health states
to explore the relationships between chronic medical condi-
tions and major depression. Simulation was employed in
order to validate and select the best model as part of the
development process. Data from two Canadian general
health surveys were used to construct the model and Monte
Carlo simulation was conducted to evaluate it. In an initial
model (model 1), incidence and cure rates were simulated
using a single transition probability, implementing a
Markov chain [17]. The results of the initial model suggest-
ed that the probability of cure declined linearly by a set
constant amount, and the model was modiﬁed in order to
incorporate this assumption, thus becoming a Markov
process [18]. The results of this model showed the best
concordance with the observed data and resulted in a
decline from the initial value to 0, which contradicted
clinical experience in the sense that a cure is possible.
Therefore, the author used an exponential equation for
the recovery decline (model 3). This model also predicts
that the decline rate can be higher in the ﬁrst weeks and
lower later on. The model was extended by substituting a
higher recovery probability and maintaining the exponen-
tial pattern by reducing the probability to 0 in some model
cycles (model 4). Death health state was added to the
Markov process and the probability was calculated,
converting the 6-year proportion into a weekly transition
probability (model 5).
The main objective of this study is to develop, retrospec-
tively validate, and select the best simulation model of a
clinical trial that evaluates the changes in cholesterol level
as a surrogate marker for lipodystrophy (distribution of
body fat) in HIV subjects under alternative antiretroviral
regimes, i.e., treatment with Protease Inhibitors vs. a com-
bination of nevirapine with other antiretroviral drugs.
2. Methods
The development methods of simulation models used in
the literature are very similar unless the study-speciﬁc
aspect is considered. We followed the following steps to
construct and validate the models: (1) obtaining the clinical
trial protocol and all information on the trial extracted
from the protocol, actual experimental data, trial investiga-
tors, and expert suggestions; (2) based on the protocol pro-
vided and the input of the trial investigator, we developed
the conceptual model of the trial including objective, end-
points, structure, and assumptions; (3) the following task
was to extract and analyze data in order to make a useful
summary of the total cholesterol level to help in construc-
tion of the model; (4) we then transformed the conceptual
model into mathematical models proposed as good candi-
dates to explain the changes in cholesterol level; (5) we then
translated the mathematical model into a computational
model using a general modeling and simulation software,
Sigma for Windows; (6) we deﬁned the validation and
selection criteria; (7) we simulated the model to assure that
the expected simulation procedure was working correctly;
(8) we simulated the model to estimate and calibrate its
parameters; (9) we obtained the standardized distance in
mean and variance for all considered endpoints, and (10)
we ﬁnally selected the best model based on the selection cri-
teria. Fig. 1 shows all these steps and the time (in full days)
required for completion of this work. The recursive arrows
represent the unit increase in time.
2.1. Data
The data used in this paper were part of a larger pub-
lished randomized clinical trial with HIV subjects
approved by the Comite´ E´tico de Investigacio´n Clı´nica
(CEIC) of the Hospital Universitari Germans Trias i
Pujol and conducted at that hospital (a complete descrip-
tion of the trial can be found in Negredo et al. [19]). As
described in that publication, the trial was a prospective,
randomized, open-label, 3-arm trial. Subjects who had
been receiving a PI-containing regimen and who had
long-lasting plasma HIV-1 RNA suppression were
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randomly assigned either to have the PI replaced by
nevirapine or efavirenz, or to continue receiving their
previous PI-containing regimen. The main objectives of
the trial were to compare the eﬃcacy of the PI-contain-
ing regimen and 2 PI-sparing regimens that included
nevirapine or efavirenz in maintaining the plasma
HIV-1 RNA suppression levels and allowing progressive
immunological improvement. Secondary objectives were
to assess the impact of PI-sparing regimens on metabolic
proﬁle, other adverse events, and quality of life. In addi-
tion, variations in body shape in subjects having lipodys-
trophy at baseline after they began receiving nevirapine
or efavirenz instead of a PI was also evaluated, in com-
parison with subjects who continued to receive PIs.
To assess the latter, the authors evaluated the changes
in total cholesterol level as a surrogate marker for
lipodystrophy. Therefore, data on the subject-based
cholesterol level of 49 (PI control treatment, n = 26;
new nevirapine treatment, n = 23) were extracted from
the overall results of this clinical trial. All subjects had
one visit at baseline and four follow-up treatment visits
at 3-month intervals thereafter. Only subjects who
ﬁnished the whole trial were included in the ﬁnal analy-
sis. Table 1 shows the evolution and relative variations
over the course of the four follow-up visits. The clinical
trial results show high outcome variability (the last visit
cholesterol level) and no statistically signiﬁcant diﬀerenc-
es were found between treatments.
The main outcome for estimation of the eﬀect of the
treatment was the cholesterol level measured at the last visit.
Two-way variance analyses on repeated measures were car-
ried out. The residuals were found to have a normal distri-
bution with a zero mean and standard deviation. This
property justiﬁes the inclusion of variability as normal dis-
tribution on the models constructed for this clinical trial.
Statistically signiﬁcant diﬀerences were found in between-
subjects variability (P < 0.05), but no diﬀerences were
revealed in within-subjects variability (P = 0.757, P > 0.05).
Both treatments showed similar eﬃcacy when assessed
at the last visit, indicating that the new drug combination
may not have any statistically signiﬁcant eﬀect in long-term
treatment. Possible reasons could be inappropriate clinical
trial design due to erroneous outcome selection for estima-
tion of the eﬀect of the treatment, the fact that the treat-
ment does not work, high variability between subjects
due to insuﬃciently restrictive inclusion or randomized cri-
teria, small sample size, incorrect statistical design or insuf-
ﬁcient statistical analysis [4,20]. Other possible reasons
could be ﬂawed selection of study population or wrong
dose [21]. Table 2 summarizes the results based on the data
obtained in the four follow-up visits. No statistically signif-
icant diﬀerence was found between the two treatments.
2.2. The model
The 2-arm parallel clinical trial can be modeled as the
addition of overall mean and variance mixed eﬀects
describing cholesterol evolution at discrete points in time
[22,23]. On this basis, formula (1) is introduced as follows:
yijT ¼ ljT þ di þ eij; ð1Þ
where yijT is the cholesterol level in i subject, j visit, and T
treatment, where T = {C,N}; j = {0,1,2,3,4}; ljT is the
mean cholesterol level at j visit and T treatment; di is the
between-subjects eﬀect size for i subject; 0 mean and Sd
standard deviation;eij is the within-subjects eﬀect size for i
subject, at j visit with 0 mean and Se standard deviation.
The model allows us to divide the random term into ran-
dom eﬀect di presented at baseline visit i (i = 0) and ﬁxed
eﬀect with the same value at follow-up visits, and the mea-
surement of random eﬀect, with diﬀerent values for each
follow-up visit including the baseline period. The same con-
cept was applied in order to study sample size requirement
Data:
Time: 6 day 
Conceptual 
model
Time : 21 days
Mathematical 
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Time :28 days
Simulation 
for error 
correction
Simulations for 
parameters estimation 
and calibration,and  
results validation
Time : 36 days
Clinical trial 
protocol 
Time:  5 days 
Computer model
Time: 31 days
 Validation Results
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Fig. 1. Development and validation of the simulation models of the
clinical trial. Time = Time + Unity (Unity = 1 day).
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and the cost of randomized clinical trial with repeated mea-
surements [4].
Four endpoints were chosen for measuring the size of
the treatment eﬀect. The ﬁrst endpoint quantiﬁes the cho-
lesterol level at the last visit (L, see formula (2)), the second
estimates the diﬀerence between the last and the baseline
visits (D, see formula (3)), the third quantiﬁes the average
diﬀerence in cholesterol level between the four follow-up
visits and the baseline visit (A, see formula (4)), and in
order to minimize the overall variability, the fourth end-
point was used to estimate linear changes in cholesterol
level from the baseline to the end of the trial, based on
the ﬁrst and last visits (V, see formula (5)).
LiT ¼ yi4T ; ð2Þ
DiT ¼ yi4T  yi0T ; ð3Þ
AiT ¼
Pj¼4
j¼1yijT
4
 yi0T ; ð4Þ
V iT ¼ 2  yi4T þ yi3T  yi1T  2  yi0T
6
. ð5Þ
Five models were developed from the general model
based on diﬀerent assumptions regarding treatment vari-
ability and cholesterol reduction patterns over time. The
models are described below.
2.2.1. Model 1
The initial model makes the following assumptions in
order to estimate input parameters:
(a) Between-subjects eﬀect di is ﬁxed over time
(di0 = di1 =    = di4) and within-subjects eﬀect eij is
random (ei0 „ ei1 „    „ ei4);
(b) between (Sd) and within-subjects variances (Se) are
equal (Sd = Se);
(c) both the new and the control treatment have the same
between-subjects variance Sd and within-subjects var-
iance Se (SdN = SdC, SeN = SeC);
(d) mean cholesterol level is not the same in the new and
control treatments, and its evolution is not constant
over time, (l0N „ l1N „    „ l4N „ l0C „ l1C „    „
l4C) (Table 1); and
(e) within-subject variance Se remains constant over time
(Se0 = Se1 =    = Se4). This model considers 12
parameters, including mean cholesterol levels.
2.2.2. Model 2
This model replaces model 1 but relaxes the strong
assumptions (b) and (c) of model 1 that between and with-
in-subjects variances are equal, and second, are diﬀerent
for each treatment, i.e., in model 2 SdN „ SdC and SeN „ SeC.
The model has 14 parameters.
2.2.3. Model 3
This model is the same as model 2, but relaxes the (e)
assumption that within-subjects variance remains con-
stant over time, to allow changes over time according
to the expression: SeN ¼ SeNbjN and SeC ¼ SeCbjC
(j = {0,1,2,3,4}). The variability changes depend on the
Table 1
Cholesterol level changes from the previous visit
Visits CL N (n = 23) CHp CL C (n = 26) CHp
xN SN xjN  xj1;N SN xC SC xjC  xj1;C SC
j0 213.74 44.43 211.65 47.62
j1 195.48 40.37 18.26 25.39 213.85 41.00 2.19 41.91
j2 200.96 35.12 5.48 24.77 215.81 46.24 1.96 36.51
j3 204.91 30.30 3.96 27.78 211.23 46.74 4.58 47.72
j4 209.70 34.90 4.78 32.17 208.88 48.31 2.35 33.04
xC ;xN : Mean cholesterol level of the control and new treatment group, respectively.
SC, SN: Cholesterol level standard deviation of control and new treatment group, respectively.
CHp: Changes in cholesterol from the previous visit xjN  xj1;N and their standard deviation SN of the new treatment, and xjC  xj1;C and SC of the
control treatment.
CL: Cholesterol level of clinical trial expressed by mean xN and standard deviation SN for the new treatment and by xC and SC for the control treatment.
Table 2
Cholesterol level of all considered endpoints
Endpoints CHb N (n = 23) CHb C (n = 26) PSD Dif
xN SN xC SC Spooled xN  xC SExNxC
L 209.70 34.90 208.88 48.31 42.56 0.81 12.18
D 4.04 37.91 2.77 50.48 45.03 1.27 12.89
A 10.98 28.44 0.79 42.63 36.68 11.77 10.50
V 0.22 15.45 1.36 20.42 18.26 1.58 5.23
xC ;xN : Mean cholesterol level of the control and new treatment group, respectively.
SC, SN: Cholesterol level standard deviation of control and new treatment group, respectively.
CHb: Changes in cholesterol from the baseline visit, mean xN and standard deviation SN for the new treatment and by xC and SC for the control treatment.
PSD: Pooled standard deviation of the two treatments expressed as Spooled.
Dif: Diﬀerences in mean cholesterol level between treatment group and control group xN  xC , and their standard error SExNxC .
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baseline variability. As a result, the rate of change b in
variance is constant over time. It was chosen to make
this rate close to 1 in order to check if the simulation
results changed compared to the previous models. In this
model there are 16 parameters.
2.2.4. Model 4
This model modiﬁes model 3 by assuming that the evo-
lution of within-subjects variance follows an exponential
equation (SeN = SeNe
bj, SeC = SeCe
bj, j = {0,1, ,2, 3,4}).
The rate of change b in variance is considered constant
over time. As in the previous model, it was chosen to make
this rate h close to 0 in order to check if the simulation
results changed compared to the previous models. The
model uses 16 parameters.
2.2.5. Model 5
This model replicates model 2 but the changes of
within-subjects variance were speciﬁed as a time-depen-
dent variance (Se1 „    „ Se4), and between-subjects vari-
ance is modiﬁed over time according to the rate of
change of the variance from the baseline (djN = bjNdC,
djC = bjCdC, j > 0). This model permits free evolution of
the between and within variability, relaxing the assump-
tions imposed on models 1, 2, 3, and 4. The model has
28 parameters.
Models were implemented using Sigma for Windows
[24], an appropriate software for discrete events modeling
and simulations that focus on these systems where
changes in any variable occur at a particular instant in
time (such as the clinical trial described here). Sigma
for Windows is based on the simple and intuitive event
graph approach to simulation modeling. Sigma is an
integrated, interactive approach to building, testing, ani-
mating, and experimenting with discrete event simula-
tions while they are running. In Sigma, the discrete
event system model (clinical trial model) is developed
using three elements. These are:
(a) state variables such as cholesterol level function,
(b) events that change the value of these variables (i.e.,
cholesterol level calculation) and
(c) relationships between the events, one event causing
another to occur (quantiﬁcation of the cholesterol
level in the second period of time after the ﬁrst level
was obtained in the ﬁrst period).
An event graph organizes sets of these three elements
into a simulation model of a clinical trial. In Fig. 2,
events are represented as nodes and the relationships
between events as arrows connecting pairs of these
nodes (A and B), and representing the condition under
which one event will cause another event to occur, after
a period of time. Using these concepts, a simulation
model of a clinical trial can be built easily and validat-
ed while the simulation is running. This software suc-
cessfully was used for the creation of diﬀerent models
types appeared in the thesis dissertation of the ﬁrst
author [1].
In Fig. 3, an event of the clinical trial is represented by
seven state variables (nodes) and six arrows (relationships).
The Assigning node allows the allocation of treatments
considered in the trial; Control and New treatment nodes
represent the Protease Inhibitors treatment and the nevira-
pine treatment, respectively, and ﬁve state variables (nodes)
were introduced for these two treatments: four related to
the follow-up visits (j = 1,2,3,4) while one represents the
baseline visit (j = 0) associated to these follow-up visits.
The general response variable model represented by
Eq. (1) was added to each visit.
2.3. Validation and selection
As mentioned before, internal validation is a compari-
son of the simulation results and those of the clinical trial.
The traditional methods for such comparisons are based on
hypothesis testing or on the conﬁdence intervals of the
means. In our study, we applied a new method of compar-
ison based on the standardized distance, in mean and var-
iance, between real data and simulated data. For any
endpoint (L,D,A,V) we deﬁned the standardized distance
in mean (SDM) and the standardized distance in variance
(SDS) as:
10% < SDM ¼ xo  xs
so
< 10%; ð6Þ
10% < SDS ¼ So  Ss
So
< 10%; ð7Þ
where xo is the observed mean value; So corresponds to
observed standard deviation; xs is the simulated mean val-
ue, and Ss is the simulated standard deviation of the L, D,
A, V endpoints. The ﬁrst validation criterion is that the
standardized distance in means values are 10% minus or
plus, as the formula (6) indicates. The second criterion is
that the standardized distance in variances are 10% minus
or plus, as the (7) indicates. The third criterion is that the
model has to reproduce these results simultaneously for
all endpoints. Selection of the best model was based on
two sequentially applied criteria: (1) the model had to meet
the three validation criteria; and (2) the most parsimonious
model (i.e., the model containing the lowest number of
parameters) fulﬁlling the previous criteria would be
selected.
A B
State variables
yiBT = µ iBT + d BT + e iBT
State variables
yiAT = µiAT + d AT + e iAT
Fig. 2. Simple discrete event graph.
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2.4. Simulation of the clinical trial
One thousand 23 (26) Monte Carlo simulations were run
through the mixed eﬀects variance model with initial
parameters of mean, Sd and Se. The ﬂowchart of the clini-
cal trial simulation model, shown in Fig. 3, is run as
follows.
The simulation started at the Assigning node so as to
allow subjects to be allocated parallel to either the control
treatment group or the new treatment group. The allocation
of the two treatments is based on treatment identiﬁcation ID
(if ID = 0 then subject receives control treatment; if ID = 1
then subject receives the new treatment). Then, at the base-
line visit j = 0. The cholesterol level (yijT) is quantiﬁed from
population distribution, applying the baseline mixed
variance eﬀects model represented by formula (1).
This model randomly chooses two values from two
normal distributions and sums them to the ﬁxed mean
cholesterol level value to obtain the overall cholesterol
level [21]. At the ﬁrst visit (j = 1), the subject’s cholesterol
level (yijT) is updated according to the mean value and the
random eﬀect term eij. The variability di is ﬁxed and is the
same as at the baseline visit, and added to mean cholester-
ol level and random variability eij. The calculation is then
repeated for the three remaining visits of the clinical trial.
The end criterion of the individual simulation is that
when a subject completes the last visit (j = 4), s/he exits
the model and the next subject enters, and so on until
all 23(26) subjects of the control and new treatment,
respectively, have been simulated and the last visit of each
one of the trial follow-ups complete. This simulation is
repeated 1000 times, changing the random seed, thus
resetting all model variables to zero. In addition, another
series of simulations was run, in which 115(130) subjects
were allocated to the control and new treatments,
respectively.
Fig. 3. Flowchart of simulation model.
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2.5. Estimation of model parameters
Estimating the input parameters using calibration
with simulation involves selecting the correct parameters
to characterize the problem under study. In this study,
we use iterative processes to estimate the input parame-
ters until the results of the model meet the validation
criteria described in the previous section. Assuming that
subjects come from the same population with a com-
mon distribution for between and within-subjects vari-
ability and that variabilities are mutually independent,
the calibration process started by summing up the two
components of variability to obtain overall variability
at the last visit (j = 4), as shown in the following
formula:
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
S2d þ S2e
q
¼ Stotal; ð8Þ
where Stotal is the result of summing the two variabilities.
Using this formula, it was easy to develop a model based
only on the results for the L endpoint. However, when
other endpoints had to be considered, simulation for each
of the models was employed.
Parameter calibration of between and within-subjects
variability of all the models depended on the observed total
variability of the last visit. The total variability was decom-
posed into two equal variabilities (between and within-sub-
jects variances). In order to calibrate the models that best
adjusted to the expected results, the distance between these
two variances was increased according to a reliability value
given as the ratio of the between-subject to overall variability
represented by standard deviation (see formula (9)). This
reliability equation was used considering the two variabili-
ties as the square of standard deviation [22].
R ¼ Sd
Sd þ Se . ð9Þ
First, the reliability value was considered less than 0.5, so
that in order to reach the required calibrated model, the
distance was increased by reducing the between-subjects
variability and raising the within-subjects variability. For
each change in the input parameters, a run of 23 and 26
subject simulations—for the new and the control treat-
ments respectively—was performed and repeated 1000
times (r) in order to reduce the diﬀerence between upper
and lower case the conﬁdence interval of the standardized
distance in variance up to 0.002. An additional simulation
series was carried out after arbitrarily but proportionately
increasing the number of subjects for each repetition to 115
and 130 subjects for the control and new treatments,
respectively, in order to reduce the diﬀerence between
upper and lower case of the conﬁdence interval to 0.001.
3. Results
First we calculated the results of the ﬁrst set of simula-
tions arising from repetition of the individual simulation
1000 times. Table 3 shows the summary statistics of these
results for all models and endpoints simultaneously. As
with the results of the clinical trial, no signiﬁcant diﬀerence
between the two treatments is shown in Table 3. The stan-
dardized distance, in means and variance of the simulation
models in Table 4, shows that all ﬁve models are within the
minus or plus interval for the L, D, and A endpoints. The
standardized distance in variance for the V endpoint is only
within the minus or plus interval in the case of models 2, 4,
and 5. However, the standardized distance trends show
that all models are within the 10% minus or plus interval.
Model 5, based on the assumption that within-subjects var-
iability of cholesterol levels changes over time, is the one
that minimizes the validity criterion, i.e., distance is equal
or 1% minus or plus. Table 5 shows the probabilities of suc-
cess of 1000 repetitions of the simulation for 245 subjects
instead of 49. The precision of the estimation is increased
by the fact that standard error decreases compared to that
of previous results. Consequently, the power of estimation
of SDS for all endpoints is much higher (Table 5). These
results also illustrate that model 5 is more eﬃcient, since
it has higher success probabilities for all endpoints. If we
leave the parsimony criterion aside, this model is the best
since it is the one that the best reproduces reality and could
therefore be used to assess the design of the clinical trials.
Model 2, however, is the best when considering the parsi-
mony criterion.
The model parameters estimated and calibrated by the
simulation are shown in Table 6. All parameters are con-
stant, except Sd and b, which correspond to model 5 and
vary over the follow-up visits.
4. Discussion and conclusion
In this research, an innovative approach for the valida-
tion and selection of a model for simulation of clinical tri-
als was applied. The mechanism used to estimate
parameters, calibrate the models, and validate their results
performed very well. Thus, it can be used to estimate
parameters of simulation models when analytical methods
do not exist or are diﬃcult to apply. Five simulation mod-
els based on data for subjects completing the clinical trial
were constructed, and an operational internal validation
was carried out against the data used in construction of
the model. Monte Carlo simulation was used based on
two approaches: population simulation and clinical trial
simulation. The ﬁrst simulated a large number of subjects
(10,000) and repeated the runs/simulations for diﬀerent
sets of parameters in order to quantify uncertainty. The
second approach simulated the population approach and
repeated it many times (1000) in order to quantify vari-
ability between repetitions. The number of such repeti-
tions depended on the desired level of precision
(SE = 0.05). These methods can be applied to evaluate
discrete state variables [25,26] and continuous state vari-
ables [27], as other authors have done in similar contexts
[28].
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The approach to model construction was similar to that
of Patten [16], but diﬀered in using mixed variance eﬀects
statistical models to represent continuous variable health
states. The rationale for using this type of modeling was
the nature and quantity of the data obtained from the clin-
ical trial. Health states were represented by the level of cho-
lesterol and linked by the logical relationships shown in
Fig. 2. We evaluated them using Monte Carlo simulation
in order to estimate the model’s results. Like Patten, our
models were based on data collected from only one clinical
trial, and may therefore not be generalizable to other
populations. Simulation can, however, be used to transfer
the ﬁndings to other contexts by adjusting the parameters,
structures, and assumptions as required.
The simulation models allowed relaxation of the strong
assumptions in model parameters; however, this implies the
addition of further parameters to the model. Hence, for
models 1, 2, 3, 4, and 5 the number of parameters rises
to 12, 14, 16, 16, and 28, respectively. Simulation also per-
mits calibration of models with complex parameter combi-
nations, such as in model 5. These results demonstrate that
model 2 meets the selection criteria; therefore we can
assume that this model is the best for optimization purpos-
es. Model 5 minimizes the validation criterion to be equal
to or 1% minus or plus. This model is the most eﬃcient
since it has the highest success probability for all endpoints
simultaneously (Table 5, success probability > 0.9). How-
ever, it is not convenient for certain applications, since
Table 3
Results of one thousand 23 (26) Monte Carlo simulations
Endpoints Model 1 Model 2 Model 3 Model 4 Model 5
xN  xC xN  xC xN  xC xN  xC xN  xC
Spooled Spooled Spooled Spooled Spooled
SExNxC SExNxC SExNxC SExNxC SExNxC
L 0.94 0.87 0.95 0.94 0.89
42.15 43.01 40.57 41.57 42.67
12.07 12.31 11.61 11.90 12.21
D 0.54 1.15 0.43 0.43 1.35
42.31 45.22 43.07 44.01 45.20
12.11 12.94 12.33 12.60 12.94
A 11.23 11.91 11.13 11.13 11.86
33.59 35.52 35.56 35.75 36.23
9.62 10.17 10.18 10.23 10.37
V 1.88 1.77 1.92 1.92 1.75
15.78 16.85 16.06 16.42 18.24
4.52 4.82 4.60 4.70 5.22
Trend 2.24 2.60 2.17 2.18 2.64
33.46 35.15 33.82 34.44 35.58
9.58 10.06 9.68 9.86 10.19
xC ;xN : Mean cholesterol level of the control and new treatment group, respectively.
Table 4
Standardized distance in mean and variance based on results of one thousand 23 (26) Monte Carlo simulations
Endpoints SDM (n = 49, r = 1000) SDS (n = 49, r = 1000)
Model 1 Model 2 Model 3 Model 4 Model 5 Model 1 Model 2 Model 3 Model 4 Model 5
L 0.003 0.002 0.003 0.003 0.002 0.010 0.010 0.047 0.023 0.003
D 0.016 0.003 0.019 0.019 0.002 0.061 0.004 0.043 0.023 0.004
A 0.015 0.004 0.018 0.018 0.002 0.084 0.032 0.030 0.025 0.012
V 0.017 0.010 0.019 0.018 0.009 0.136 0.077 0.120 0.101 0.001
Trend 0.012 0.002 0.014 0.014 0.001 0.061 0.014 0.051 0.034 0.001
Table 5
Success probabilities of all endpoints based on results of one thousand 115 (130) Monte Carlo simulations
Endpoints PS (n = 245, r = 1000) PS (n = 245, r = 1000)
Model 1 Model 2 Model 3 Model 4 Model 5 Model 1 Model 2 Model 3 Model 4 Model 5
L 0.86 0.87 0.89 0.88 0.89 0.97 0.95 0.92 0.97 0.96
D 0.89 0.87 0.89 0.88 0.88 0.96 0.98 0.91 0.96 0.98
A 0.90 0.88 0.89 0.88 0.86 0.96 0.96 0.90 0.96 0.98
V 0.91 0.90 0.92 0.91 0.88 0.47 0.71 0.30 0.47 0.97
PS: Success probability.
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there are many parameters that need to be simultaneously
speciﬁed and calibration may therefore be problematic. In
any case, the problem can be solved by considering param-
eter optimization through simulation (i.e., assigning inter-
vals of values to each input parameter and simulating all
possible combinations to ﬁnd the optimal input parame-
ters). To perform that, the use of a supercomputer is
strongly recommended in order to generate large number
of simulations at minimum time. This mechanism for
parameter estimation can be applied to any given mixed
variance model.
We found that the variability of the main clinical trial
outcome was very high (Table 3). For example, the pooled
standard error according to model 2 was 12.31. Contrast-
ing that result with the result of the trial, the simulation
model was able to determine that there was a low probabil-
ity of success in obtaining signiﬁcant results with the trial.
Therefore, the simulation models would suggest not pro-
ceeding. This problem might be caused by an error in out-
come deﬁnition, i.e., if the trial results were based on the
average changes from baseline (endpoint A in Table 4),
the success probability of the modeled trial could be
increased by simulating more subjects. This information
is useful in answering clinical questions such as: what is
the most eﬃcient endpoint for the clinical trial?
Performing operational validation (results validation)
might be suﬃcient in order to assess validated conceptual
models and validated computer models. Nevertheless, one
question remains unanswered: what should the cut-point
be for the model goodness of ﬁt (10% or 1%?) in order to
be conﬁdent that it will reproduce future clinical trial data.
Therefore, validation and selection can consider additional
criteria, such as relative capacity of prediction between
models. This criterion can only be applied if we validate
the model with other data. Alternatively, this can be done
by constructing the model with retrospective data and car-
rying out sensitivity analysis in order to approximate it to
the proposed clinical trial, as some authors have done [20].
For instance, Monte Carlo simulation was used to evaluate
a survival model to validate it and estimate the eﬀects of
treatments [29]. The simulated survival curve was
compared to the observed curve. Other authors proposed
collecting data from clinical trials and other sources in
order to calibrate and validate any model with prediction
purposes [2,30].
In summary, simulation, as a rule, is used to reﬁne clin-
ical trial models in estimating and calibrating their param-
eters, and help decision makers in evaluation of their study
results. Model validation by simulation under standardized
distance in mean and variance is an innovative approach,
and might be extended to other purposes, such as the
assessment of eﬃcacy, safety, and equivalence of treat-
ments in clinical trials. For example, it could be applied
to calculate the success probability of not ﬁnding diﬀerenc-
es between two treatments under equal variability.
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